BioChina International 2012-Biopharma and Bioprocessing Congress June 26 and 27 Shanghai, China
On the way to achieve antibody industrialization, China is faced with challenges in transforming good research into effective products that can be reproduced in large quantities and meet all regulatory and quality standards. The key to overcome above challenges lies in bioprocess. Advancements on scale-up, pilot production, purification, expression technologies, quality control etc are some key issues that the industry stakeholders need to take into consideration when working on strategies to bring China’s biopharma industry into the next level . Apart from challenges in bioprocess technologies, China is working toward to better biosimilar and antibody R&D to fill limited product pipelines. With patent cliff for most of biologics in 2015, biosimilar has been recognized as great opportunities and major trends for future biopharma’s industry.
Riding on the booming biopharma industry in China, the inaugural BioChina International Conference 2012 is positioned to be the largest biopharma conference in China to focus on latest bioprocess and antibody advancement in China and globally. The content rich conference aims to build a definitive platform for biopharma industry leaders to gain proven strategies and solutions to finding new targets, optimizing epitope design for monoclonal antibody, scaling up both upstream and downstream processes, building pilot plant, advancing cell line development, improving quality and ensuring comparability of mAbs, biosimilars, biobetters and vaccines.
For more information, please contact Daniel Chen at 8621-32516046 or email email@example.com for more information. Event website: http://bci2012.shinemediaworld.com/